|Articles|June 1, 2015
- Applied Clinical Trials-06-01-2015
- Volume 24
- Issue 6
Applied Clinical Trials Digital Edition - June/July 2015
Regulatory: Solving Generic Cliff with 505(b)(2) The U.S. Biosimilar Pathway Trial Design: Modeling & Simulation Strategies Lifecycle Management: Bridging Economic & Clinical Value Also in this issue: EMA's Dueling Tones on Regulatory Vision Regulatory Compliance: The Site Burden Assessing Safety for Follow-on NBCDs
Advertisement
Articles in this issue
about 11 years ago
FDA Seeks Resources to Support New Research Initiativesabout 11 years ago
Safety Considerations for Follow-On Non-Biologic Complex Drugsabout 11 years ago
Putting the EMA House in Orderabout 11 years ago
Experts Call for Urgent Action on Antibiotics Researchabout 11 years ago
Oncology Leads Personalized Medicineabout 11 years ago
Characterizing the Real Cost of Site Regulatory Complianceabout 11 years ago
Using 505(b)(2) to Solve Shortfall from Generic Cliffabout 11 years ago
Lifecycle Modeling and Simulation in Clinical Trialsabout 11 years ago
The U.S. Biosimilar Pathway: Policy Precedes Scienceabout 11 years ago
Managing Portfolios for Economic and Clinical ValueAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Agentic RTSM and the Push to Compress Clinical Trial Startup: Q&A with Robert Hummel, Suvoda
2
AI-Driven Clinical Trial Recruitment and Design
3
Why Clinical Trials Need an Execution Architecture Before AI Can Deliver: Q&A with Abraham Gutman, AG Mednet
4
How RBQM Needs to Evolve for a Real-Time Oversight World
5